Meropenem to Children with Febrile Neutropenia Induces Monoresistant Pseudomonas aeruginosa

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

  • Mette B. Mønster
  • Nadja H. Vissing
  • Henrik Schrøder
  • Dorthe Grosen
  • Steen Rosthøj
  • Niels Frimodt-Møller
  • Mikala Wang
  • Henrik C. Schønheyder
  • Schmiegelow, K.
  • Ulrik S. Justesen
  • Nygaard, Ulrikka

Antimicrobial resistance in Pseudomonas aeruginosa is a threat to children with cancer. We explored the association between P. aeruginosa resistance and previous antibiotic exposure. All children with cancer and P. aeruginosa bacteremia in 2007 to 2016 in Denmark, a country with an overall resistance rate of ~3%, were included. Twenty percent (10/49) of isolates from children previously exposed to meropenem were meropenem nonsusceptible. The only significant risk factor of meropenem nonsusceptibility was previous meropenem therapy (P=0.03). On the basis of these results, we suggest that meropenem should be reserved as a last resort for children with febrile neutropenia in countries with low antimicrobial resistance.

OriginalsprogEngelsk
TidsskriftJournal of Pediatric Hematology/Oncology
Vol/bind42
Udgave nummer8
Sider (fra-til)e783-e787
ISSN1077-4114
DOI
StatusUdgivet - 2020

Bibliografisk note

Funding Information:
Supported by the Danish Cancer Society (reference no. R190-A11731), the Danish Childhood Cancer Foundation (reference no. 2017-2105) and Dagmar Marshalls Fund.

Funding Information:
The study received no financial support from National Institutes of Health (NIH), Wellcome Trust or Howard Hughes Medical Institute (HHMI). The funding organizations played no part in the design of the study or the analysis of the results.

Publisher Copyright:
© 2020 Wolters Kluwer Health, Inc. All rights reserved.

ID: 262741964